U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07007780) titled 'Lutikizumab in Neoadjuvant Treatment of Early-Stage TNBC' on May 26.
Brief Summary: To explore the application of Lutikizumab in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Lutikizumab in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Lutikizumab and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Triple -Negative Breast Cancer
Intervention:
DRUG: Lutikizumab monotherapy
Lutikizumab monotherapy before surgery at a dose of 5mg/kg, ...